Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators

BACKGROUND: Immune checkpoint blocker (ICB) has shown significant clinical activity in melanoma. However, there are no clinically approved biomarkers to aid patient selection. We aimed to identify patients with advanced or metastatic melanoma who are likely to benefit from ICB monotherapy using easi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Byun, Hwa Kyung, Chang, Jee Suk, Jung, Minkyu, Koom, Woong Sub, Chung, Kee Yang, Oh, Byung Ho, Roh, Mi Ryung, Kim, Kyung Hwan, Lee, Choong-Kun, Shin, Sang Joon
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8190329/
https://ncbi.nlm.nih.gov/pubmed/34123816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.659754
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados